Mandate

Vinge advises Sveafastigheter on the establishment of its EMTN programme and issuance of EUR 300 million bonds

Vinge has advised Sveafastigheter AB (publ) as Swedish legal counsel on the establishment of a euro medium-term note programme (the “EMTN programme”) with a framework of EUR 2 billion and the issuance of senior unsecured bonds totalling EUR 300 million under the EMTN programme.

On 20 January 2026, Sveafastigheter issued bonds in an amount of EUR 300 million with a tenor of five years and a coupon of 4.375 per cent with the proceeds being party used to refinance Sveafastigheter’s outstanding bonds with ISIN SE0022244018. Goldman Sachs Bank Europe SE, J.P. Morgan SE, Danske Bank A/S, Nordea Bank Abp, Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) acted as dealers in connection with the transaction. The offering circular was approved by Euronext Dublin on 5 January 2026.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda, Calle Tengwall Pagels, August Ahlin, William Carlberg Johansson and Ida Appelgren.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026